We promise a united front.

Cuong Do

Founder and Chairman

Cuong Do is the founder and chairman of M6P Therapeutics, his third biotech startup. He previously founded Callidus Biopharma and Lysodel Therapeutics. Amicus Therapeutics acquired Callidus for its drug for Pompe disease.

Cuong retired in December 2020 as President of Samsung’s Global Strategy Group, where he helped set the strategic direction of the Group's diverse businesses, including its biosimilars and biologics contract manufacturing businesses. He was also the Chief Strategy Officer for Merck, Tyco Electronics, and Lenovo. In addition to founding biotech companies, Cuong also founded four high-tech companies, including CareVisor, Identifor, and Fitwise.

He serves or has served on the board of AngioSafe, BioVie, Curve Financial, Hope Trust, ILiAD Biotechnologies, Laava, RenalSense, and WuXi AppTec (the world's largest contract research organization serving the pharmaceutical industry). He also serves or served on the board of Autism Speaks, Caring for Cambodia, Celebrate the Children school, Fulbright University Vietnam, the Institute for Exceptional Care, Newark Academy, Profectum Foundation, and the Tuck School of Business.

Cuong received his BA in Biochemistry and Economics from Dartmouth College and an MBA from the Tuck School of Business at Dartmouth.

Russell Gotschall

VP, R&D

Russell is the VP of R&D and brings more than 25 years of drug discovery and development to M6P Therapeutics. Prior to joining M6P, Russell served as VP of R&D at Amicus Therapeutics, where he managed pre-clinical R&D and helped build a world-class discovery and research organization that maximizing protein engineering and analytics capabilities in the developing of a robust pipeline of novel gene therapy programs in collaboration with the University of Pennsylvania.

Russell has had a long career in the clinical and biopharmaceutical industry utilizing his glycobiology expertise to support the development of analytical assays to understand pediatric pharmacology and to support drug development of advanced therapeutics for rare diseases.

His experience spans multiple indications including lysosomal storage diseases, cardiovascular, mineral metabolism disorders, and chronic kidney disease. Russell is a graduate of Wichita State University with a master’s degree in biology with an emphasis in glycobiology.

Eric Grinstead

Commercial

Eric provides commercial, operations, and leadership capabilities to M6P Therapeutics. For over 30+ years, he held specific functional responsibilities for sales, marketing, supply chain, operations, pricing, reimbursement, policy, government affairs, strategy, communications, and early access programs, both in local and global domains – and sat on management teams in the last 15 years – at Alexion, Synageva, and Clementia with general responsibilities for commercializing ultraorphan drugs. Additionally, Eric served as President of the Safety Net Foundation and the Complement Foundation, two not–for–profit entities that provide drugs at no cost to qualified individuals.

Bernadette Keane

CMC & Quality

Bernadette is the Principal Consultant at Keane Consulting LLC and has over 25 years experience in the biopharmaceutical industry, providing CMC/Regulatory/Quality strategic and operational support for start-up to mid-sized biotech companies, specializing in innovative gene and cell therapies, biologics and small molecules. Throughout her career, Bernadette gained experience in a broad array of products, providing strategic, technical, and operational support for development programs transitioning from research into development, through the development pipeline into clinical trials and commercialization. Prior to establishing Keane Consulting LLC, Bernadette held the position of VP Quality at bluebird bio for several years. In addition to providing consulting services to multiple companies throughout her career, Bernadette held positions of increasing responsibility in Quality, Regulatory, Process development and Analytical development at Tolerx, T Cell Sciences, and ImmunoGen.

Pawel Krysiak

President & CEO

Pawel is a biotechnology executive with 20 years of experience in rare diseases, oncology, and digital health. His previous experience includes President & CEO of Seva Therapeutics, VP of Sales and Business Development at EmpiraMed, VP of Commercial and Operations at Ceerdis Corporation, Area Director & General Manager at BioMarin Pharmaceuticals, as well as progressively important sales, marketing, and commercial strategy roles at Genzyme Corporation. Mr. Krysiak started his career in specialty sales at Merck.

Pawel obtained a Bachelor of Science in both Biomedical Sciences and Biochemistry from the University of Guelph and a Master of Science in Molecular Physiology from the University of Western Ontario. In addition, he received executive business training from Ivey Business School and continuing business education from Harvard Business School.

Lin Liu

Director, R&D

Lin Liu, Director of R&D at M6P Therapeutics, is co-inventor of a modified version of the GlcNAc-1-phosphotransferase enzyme and co-author of the patent application for it. Dr. Liu was previously a post-doctoral fellow in Dr. Kornfeld’s lab.

Gavin Maitland

Finance

Gavin Maitland is a finance executive with 25 years of experience, the last 14 in the life sciences sector. Prior to his CFO role at M6P Therapeutics, he has delivered fractional CFO support and consulting services to life science companies across therapeutic areas in both device and drug companies.

He has previously held positions as Chief Financial Officer at IP Group plc, a listed venture capital fund in London and APP Group, an IT services portfolio company of Warburg Pincus in Prague, Czech Republic. Previously, he worked for TNT Express Worldwide, where he delivered internal financial audits and systems reviews in global subsidiary companies and served as the financial controller in subsidiary companies in Singapore, France, and Eastern Europe. Gavin began his business career as an auditor with Price Waterhouse Coopers.

Gavin is a graduate of the University of Dundee, Scotland, is a member of the Institute of Chartered Accountants of Scotland (ICAS) and holds an MBA from London Business School.

Gavin Malenfant

Portfolio

Gavin is a leader in corporate strategy and drug development in the biopharmaceutical industry with deep experience in rare disease. He previously led Genzyme’s rare disease development function resulting in commercialization of Aldurazyme®, Myozyme®, Lumizyme®, Cerdelga® and Fabrazyme®, products and then Head of Operations with Genzyme a Sanofi company.

Malenfant went on to lead efforts for the approval of Exondys 51 with Sarepta Therapeutics and prepared the company for commercialization of Exondys 51, delivering a novel therapeutic to patients with Duchenne muscular dystrophy.

Malenfant earned a B.S. degree in biology from the University of Boston Massachusetts. In addition, he received continuing executive business training from MIT Sloan School.